Ep. 395 - ESMO analysis & Auchincloss proposal
BioCentury This Week

Ep. 395 - ESMO analysis & Auchincloss proposal

Nov 3, 2026
33:11
S7 · E395
-(0)

About this episode

A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the findings and Representative Jake Auchincloss' Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us biobank. The analysts also discuss how U.S. investors are reacting to Treasury's proposed COIN...

Comments

Rate this episode

Episode Details

Author
BioCentury
Show Type
full
Audio Format
audio/mpeg

We use analytics

We use Umami, a privacy-friendly analytics tool, to understand how visitors use this site. No personal data is collected and no data leaves our EU servers. You can accept or decline below. Privacy Policy